1 Beaten-Down Growth Stock You'd Regret Not Buying on the Dip, According to Wall Street
Looking at the performance of Bluebird Bio (NASDAQ: BLUE) over the past three years, one wouldn't guess that it is one of the rare gene-editing specialists that has not just one but two approved products on the market in the U.S. The biotech's shares are down by 87% over this period. Is there any hope for Bluebird?
Some think so. From its current share price of $3.42, Wall Street analysts believe the stock could jump by 115% within a year. Their average price target is $7.36. Meeting these expectations is one thing, but performing consistently well after that is another.
Let's find out whether Bluebird's shares are worth buying while they are still down.
Source Fool.com
